Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | SCN1A | P35498 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351076 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL6949727 | 0.95 | KMT2A (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL29383650 | 0.95 | KMT2A (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL2636596 | 0.95 | KMT2A (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL6949730 | 0.94 | MAPT (0.44) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL17263514 | 0.92 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL10748158 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL9570762 | 0.89 | MAPT (0.42) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL6955248 | 0.89 | LMNA (0.54) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E | |
| SCHEMBL18157025 | 0.87 | KMT2A (0.44) | ALDH1A1SMN1; SMN2MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3408266-B1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | ATATUERK UENIVERSITESI BILIMSEL ARASTIRMA PROJELERI BIRIMI (TR) | 2020-11-18 | — | — | EP | claimed |
| US-10758521-B2 | N3,N6-bis(2-(5-methoxy-1H-indole-3-yl)ethyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxamide and use thereof in the field of neurotoxicity | HCM BIOSCIENCE SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2020-09-01 | — | — | US | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111097050-A | Composition comprising fatty acid or derivative thereof and phenylpyridine derivative | 黄泳华 | 2020-05-05 | — | — | CN | claimed |
| US-20190290628-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | HCM BIOSCIENCE SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2019-09-26 | — | — | US | claimed |
| US-20190038612-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | HCM BIOSCIENCE SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2019-02-07 | — | — | US | claimed |
| EP-3408266-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | Atatürk Üniversitesi Bilimsel Arastirma Projeleri Birimi (TR) | 2018-12-05 | — | — | EP | claimed |
| WO-2017131601-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | ATATURK UNIVERSITESI BILIMSEL ARASTIRMA PROJELERI BIRIMI (TR) | 2017-08-03 | — | — | WO | claimed |
| EP-1023267-B1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL SA (CH) | 2003-09-17 | — | — | EP | claimed |
| EP-1023267-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2000-08-02 | — | — | EP | claimed |
| WO-1999019302-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 1999-04-22 | — | — | WO | claimed |
| CN-119192062-A | Preparation liquid chromatography method for separating nifedipine photodegradation impurities | 天津力生制药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-116466000-A | Method for rapidly determining 176 PPCPs content in source water | 福建省产品质量检验研究院(福建省缺陷产品召回技术中心) | 2023-07-21 | — | — | CN | disclosed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | disclosed |
| WO-2000051643-A1 | USE OF GALLIC ACID ESTERS TO INCREASE BIOAVAILABILITY OF ORALLY ADMINISTERED PHARMACEUTICAL COMPOUNDS | AVMAX, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-1023267-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2000-08-02 | — | — | EP | disclosed |
| EP-0662321-B1 | Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999019302-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 1999-04-22 | — | — | WO | disclosed |
| EP-0662321-A1 | Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons | EGIS GYOGYSZERGYAR RT. (HU) | 1995-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290628-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | NLN, CASP3, AANAT | ALDH1A1 564/4885SMN1; SMN2 120/4885MAPT 633/4885 |
| US-20190038612-A1 | N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY | NLN, CASP3, AANAT | ALDH1A1 564/4885SMN1; SMN2 120/4885MAPT 633/4885 |
| US-10758521-B2 | N3,N6-bis(2-(5-methoxy-1H-indole-3-yl)ethyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxamide and use thereof in the field of neurotoxicity | NLN, CASP3, AANAT | ALDH1A1 564/4885SMN1; SMN2 120/4885MAPT 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.